TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET 27
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 29
1.6 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 TEST TYPE SEGMENT LIFELINE CURVE 38
2.8 MARKET END USER COVERAGE GRID 39
2.9 DBMR MARKET POSITION GRID 40
2.10 VENDOR SHARE ANALYSIS 41
2.11 SECONDARY SOURCES 42
2.12 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 45
4.1 PESTLE ANALYSIS 48
4.2 PORTER'S FIVE FORCES MODEL 49
5 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 50
6 REGULATORY FRAMEWORK 52
6.1 REGULATORY SCENARIO IN THE U.S 52
6.2 REGULATORY SCENARIO IN JAPAN 52
6.3 REGULATORY SCENARIO IN CHINA 53
7 MARKET OVERVIEW 54
7.1 DRIVERS 56
7.1.1 RISING INCIDENCE OF BLADDER CANCER GLOBALLY 56
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 56
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 57
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 57
7.2 RESTRAINTS 58
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 58
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 58
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 58
7.3 OPPORTUNITIES 59
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 59
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 59
7.3.3 INCREASE IN THE GERIATRIC POPULATION 60
7.4 CHALLENGES 60
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 60
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 61
8 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 62
8.1 OVERVIEW 63
8.2 CYSTOSCOPY 66
8.3 URINE LAB TEST 66
8.3.1 URINE CYTOLOGY 68
8.3.2 URINALYSIS 68
8.3.3 URINE TUMOR MARKER TEST 68
8.3.4 URINE CULTURE 68
8.3.5 OTHERS 68
8.4 BIOPSY 68
8.5 IMAGING TEST 69
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 70
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 70
8.5.3 ULTRASOUND 70
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 71
8.6 OTHERS 71
9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 72
9.1 OVERVIEW 73
9.2 STAGE IV 76
9.3 STAGE III 76
9.4 STAGE II 77
9.5 STAGE I 78
10 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 80
10.1 OVERVIEW 81
10.2 TRANSITIONAL CELL BLADDER CANCER 84
10.3 SQUAMOUS CELL BLADDER CANCER 85
10.4 OTHER CANCER TYPES 86
11 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 87
11.1 OVERVIEW 88
11.2 HOSPITAL 91
11.3 DIAGNOSTIC IMAGING CENTERS 91
11.4 CANCER RESEARCH INSTITUTES 92
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 93
11.6 ASSOCIATED LABS 94
12 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 95
12.1 OVERVIEW 96
12.2 DIRECT TENDER 99
12.3 RETAIL SALES 99
13 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 101
13.1 OVERVIEW 102
13.2 NORTH AMERICA 107
13.2.1 U.S. 114
13.2.2 CANADA 116
13.2.3 MEXICO 118
13.3 EUROPE 120
13.3.1 GERMANY 127
13.3.2 FRANCE 129
13.3.3 U.K. 131
13.3.4 ITALY 133
13.3.5 SPAIN 135
13.3.6 RUSSIA 137
13.3.7 TURKEY 139
13.3.8 NETHERLANDS 141
13.3.9 BELGIUM 143
13.3.10 SWITZERLAND 145
13.3.11 REST OF EUROPE 147
13.4 ASIA-PACIFIC 148
13.4.1 CHINA 155
13.4.2 INDIA 157
13.4.3 JAPAN 159
13.4.4 SOUTH KOREA 161
13.4.5 THAILAND 163
13.4.6 SINGAPORE 165
13.4.7 INDONESIA 167
13.4.8 MALAYSIA 169
13.4.9 PHILIPPINES 171
13.4.10 AUSTRALIA 173
13.4.11 REST OF ASIA-PACIFIC 175
13.5 SOUTH AMERICA 176
13.5.1 BRAZIL 183
13.5.2 ARGENTINA 185
13.5.3 REST OF SOUTH AMERICA 187
13.6 MIDDLE EAST AND AFRICA 188
13.6.1 SOUTH AFRICA 195
13.6.2 SAUDI ARABIA 197
13.6.3 U.A.E 199
13.6.4 EGYPT 201
13.6.5 ISRAEL 203
13.6.6 REST OF MIDDLE EAST AND AFRICA 205
14 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 206
14.1 COMPANY SHARE ANALYSIS: GLOBAL 206
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 207
14.3 COMPANY SHARE ANALYSIS: EUROPE 208
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 209
15 SWOT ANALYSIS 210
16 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET 211
16.1 F. HOFFMANN- LA ROCHE LTD 211
16.1.1 COMPANY SNAPSHOT 211
16.1.2 REVENUE ANALYSIS 211
16.1.3 COMPANY SHARE ANALYSIS 212
16.1.4 PRODUCT PORTFOLIO 212
16.1.5 RECENT DEVELOPMENTS 212
16.2 MERCK KGAA 213
16.2.1 COMPANY SNAPSHOT 213
16.2.2 REVENUE ANALYSIS 213
16.2.3 COMPANY SHARE ANALYSIS 214
16.2.4 PRODUCT PORTFOLIO 214
16.2.5 RECENT DEVELOPMENT 214
16.3 THERMO FISHER SCIENTIFIC INC. 215
16.3.1 COMPANY SNAPSHOT 215
16.3.2 REVENUE ANALYSIS 215
16.3.3 COMPANY SHARE ANALYSIS 216
16.3.4 PRODUCT PORTFOLIO 216
16.3.5 RECENT DEVELOPMENT 216
16.4 KONINLIJKE PHILIPS N.V. 217
16.4.1 COMPANY SNAPSHOT 217
16.4.2 REVENUE ANALYSIS 217
16.4.3 COMPANY SHARE ANALYSIS 218
16.4.4 PRODUCT PORTFOLIO 218
16.4.5 RECENT DEVELOPMENT 218
16.5 BIO-RAD LABORATORIES, INC. 219
16.5.1 COMPANY SNAPSHOT 219
16.5.2 COMPANY SNAPSHOT 219
16.5.3 COMPANY SHARE ANALYSIS 220
16.5.4 PRODUCT PORTFOLIO 220
16.5.5 RECENT DEVELOPMENT 220
16.6 ABBOTT 221
16.6.1 COMPANY SNAPSHOT 221
16.6.2 REVENUE ANALYSIS 221
16.6.3 PRODUCT PORTFOLIO 222
16.6.4 RECENT DEVELOPMENT 222
16.7 AGILENT TECHNOLOGIES, INC. 223
16.7.1 COMPANY SNAPSHOT 223
16.7.2 REVENUE ANALYSIS 223
16.7.3 PRODUCT PORTFOLIO 224
16.7.4 RECENT DEVELOPMENT 224
16.8 AMBU A/S 225
16.8.1 COMPANY SNAPSHOT 225
16.8.2 REVENUE ANALYSIS 225
16.8.3 PRODUCT PORTFOLIO 226
16.8.4 RECENT DEVELOPMENT 226
16.9 BD 227
16.9.1 COMPANY SNAPSHOT 227
16.9.2 REVENUE ANALYSIS 227
16.9.3 PRODUCT PORTFOLIO 228
16.9.4 RECENT DEVELOPMENT 228
16.10 CANON MEDICAL SYSTEMS CORPORATION 229
16.10.1 COMPANY SNAPSHOT 229
16.10.2 REVENUE ANALYSIS 229
16.10.3 PRODUCT PORTFOLIO 230
16.10.4 RECENT DEVELOPMENT 230
16.11 CEPHEID 231
16.11.1 COMPANY SNAPSHOT 231
16.11.2 REVENUE ANALYSIS 231
16.11.3 PRODUCT PORTFOLIO 232
16.11.4 RECENT DEVELOPMENTS 232
16.12 FUJIFILM CORPORATION 233
16.12.1 COMPANY SNAPSHOT 233
16.12.2 REVENUE ANALYSIS 233
16.12.3 PRODUCT PORTFOLIO 234
16.12.4 RECENT DEVELOPMENTS 234
16.13 GENERAL ELECTRIC COMPANY 235
16.13.1 COMPANY SNAPSHOT 235
16.13.2 REVENUE ANALYSIS 235
16.13.3 PRODUCT PORTFOLIO 236
16.13.4 RECENT DEVELOPMENTS 236
16.14 HOLOGIC INC. 237
16.14.1 COMPANY SNAPSHOT 237
16.14.2 REVENUE ANALYSIS 237
16.14.3 PRODUCT PORTFOLIO 238
16.14.4 RECENT DEVELOPMENT 238
16.15 ILLUMINA INC 239
16.15.1 COMPANY SNAPSHOT 239
16.15.2 REVENUE ANALYSIS 239
16.15.3 PRODUCT PORTFOLIO 240
16.15.4 RECENT DEVELOPMENTS 240
16.16 MINFOUND MEDICAL SYSTEMS CO., 241
16.16.1 COMPANY SNAPSHOT 241
16.16.2 PRODUCT PORTFOLIO 241
16.16.3 RECENT DEVELOPMENTS 241
16.17 NEUSOFT CORPORATION 242
16.17.1 COMPANY SNAPSHOT 242
16.17.2 COMPANY SNAPSHOT 242
16.17.3 PRODUCT PORTFOLIO 243
16.17.4 RECENT DEVELOPMENT 243
16.18 QIAGEN 244
16.18.1 COMPANY SNAPSHOT 244
16.18.2 REVENUE ANALYSIS 244
16.18.3 PRODUCT PORTFOLIO 245
16.18.4 RECENT DEVELOPMENT 245
16.19 SIEMENS HEALTHCARE GMBH 246
16.19.1 COMPANY SNAPSHOT 246
16.19.2 REVENUE ANALYSIS 246
16.19.3 PRODUCT PORTFOLIO 247
16.19.4 RECENT DEVELOPMENT 248
16.20 TIME MEDICAL HOLDING. 249
16.20.1 COMPANY SNAPSHOT 249
16.20.2 PRODUCT PORTFOLIO 249
16.20.3 RECENT DEVELOPMENTS 249
17 QUESTIONNAIRE 250
18 RELATED REPORTS 253

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.